Full-Time

Clinical Oncology Specialist

Lung Oncology

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Genetic testing and diagnostics solutions provider

Compensation Overview

$195k - $225k/yr

+ Base Salary + Commissions + Car Allowance + Restricted Stock Units (RSUs)

Senior

Company Historically Provides H1B Sponsorship

Pennsylvania, USA + 5 more

More locations: Delaware, USA | Jackson Township, NJ, USA | Virginia, USA | West Virginia, USA | Maryland, USA

The territory includes Pennsylvania, West Virginia, Maryland, New Jersey, Delaware, and Virginia. Frequent travel is required, approximately 75% of the time.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Requirements
  • Bachelor’s degree required
  • 5+ years of experience with consistent success in Hematology/Lung Oncology, Surgical or molecular diagnostics preferred
  • Deep knowledge of academic and community oncology markets, precision medicine, and reimbursement landscape
  • Ability to travel frequently, including overnight travel as needed
  • Valid driver’s license and safe driving record
  • Proven leadership, business acumen, and strong communication skills
  • Travel: ~75% (combination of road and air travel)
Responsibilities
  • Develop and execute a strategic territory plan focused on growth and account penetration
  • Identify and engage KOLs and key accounts to integrate Signatera into clinical decision-making
  • Drive new business development while expanding and deepening existing relationships
  • Maximize return on investment through consistent sales activity and cross-functional collaboration
  • Deliver impactful clinical education to physicians and care teams
  • Serve as a trusted resource in a fast-paced, startup-like environment
  • Build deep understanding of Natera’s oncology solutions, internal processes, and competitor landscape
  • Call on targeted physicians and practices to promote Natera’s oncology products and services
  • Drive product adoption by influencing clinical decision-making at the provider and system level
  • Monitor account performance and market trends; escalate issues and identify new opportunities
  • Consistently conduct business in an ethical, transparent, and professional manner
Desired Qualifications
  • 5+ years of experience with consistent success in Hematology/Lung Oncology, Surgical or molecular diagnostics preferred

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera also offers tests for family planning and prenatal screening, including the Panorama NIPT, which has conducted over 2 million tests. The company generates revenue through testing services and kits, often reimbursed by insurance, and provides genetic counseling for personalized patient support.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for personalized medicine supports Natera's genetic testing services.
  • The global NIPT market is expected to reach $7.3 billion by 2025.
  • Increased adoption of liquid biopsy tests aligns with Natera's cfDNA focus.

What critics are saying

  • Expansion into new Austin space could strain financial resources.
  • Increased competition from companies like Lantheus Holdings threatens market share.
  • HEROES trial for breast cancer may face regulatory hurdles or delays.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for diverse medical applications.
  • Their Signatera test offers personalized ctDNA analysis for cancer patients.
  • Natera's Panorama NIPT has conducted over 2 million non-invasive prenatal tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

5%
PRWeb
May 30th, 2025
The Melanoma Research Foundation To Host The Denver Miles For Melanoma 5K

The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT. We are excited to share that Kyle Speller, PA Announcer for the Denver Nuggets, will be returning as our emcee on event day! We're also excited to welcome back local sponsor, Cara Mia Dermatology, who will be providing free on-site skin screenings—helping our community stay sun-safe while supporting a great cause.DENVER, May 29, 2025 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) is thrilled to announce the next event in its annual Miles for Melanoma nationwide 5K program, bringing together local melanoma patients, supporters, care partners and thrivers. This year we will be hosting our annual Denver event on Saturday, June 14, 2025 at Sloan Lake Park at 7:30 AM MT. Opening Ceremonies will start at 8:30 AM MT and our race will kick off promptly at 9:00 AM MT

Intelligence360
May 15th, 2025
Natera To Spend $9.9 Million To Occupy 30,000 Square Feet Of Space In Austin Texas.

Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas. Natera to spend $9.9 Million to occupy 30,000 square feet of space in Austin Texas.Austin, Texas — According to state and local development sources, Natera plans to invest $9,900,000.00 to build out 30,000 square feet of new space in Austin. The company plans to occupy the new space at 13011A McCallen Pass in Austin, on or about January 1, 2026. According to the company website Natera is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, womens health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment

TXBN
Apr 24th, 2025
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera(TM) Genome MRD Test

Natera announces broad clinical launch of ultra-sensitive signatera(tm) genome MRD test.

Slater Sentinel
Apr 3rd, 2025
DnB Asset Management AS Invests $235,000 in Natera, Inc. (NASDAQ:NTRA)

DnB Asset Management AS invests $235,000 in Natera, Inc. (NASDAQ:NTRA).

TXBN
Mar 25th, 2025
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting

AUSTIN, Texas - (BUSINESS WIRE) - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025.